Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Radiation + Tislelizumab + Chemo in Esophageal SCC
NCT06446726Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Sichuan University. Primary endpoint: Pathologic Complete Response. Started Jun 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06446726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06446726.